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Abstract
Objective
This longitudinal study aimed to assess changes in retinal structure and visual function fol-
lowing a ﬁrst-ever episode of acute optic neuritis (ON).
Methods
Clinical and optical coherence tomography (OCT) data obtained over a period of 12 months
were retrospectively analyzed in 41 patients with a ﬁrst-ever clinical episode of acute ON. OCT
scans, high-contrast visual acuity (HCVA), and low-contrast visual acuity (LCVA) were ac-
quired at baseline and at 1, 3, 6, and 12 months thereafter. Macular ganglion cell and inner
plexiform layer (GCIP), peripapillary retinal nerve ﬁber layer (pRNFL), and macular inner
nuclear layer (INL) thicknesses were assessed by OCT. Linear mixed-eﬀects models were used
to analyze OCT variables of ipsilateral ON and contralateral non-ON (NON) eyes over time.
Results
The mean change of GCIP thickness in ON eyes was signiﬁcant at all follow-up time points,
with nearly 75% of the total reduction having occurred by month 1. In ON eyes, thinner GCIP
thickness at month 1 correlated with lower LCVA at month 3. Mean pRNFL thickness in ON
eyes diﬀered signiﬁcantly from NON eyes at all postbaseline time points. INL thickness was
signiﬁcantly increased in ON eyes (month 1) but also in contralateral NON eyes (month 12).
Conclusions
Retinal structural damage develops rapidly following acute ON and is associated with sub-
sequent functional visual deﬁcits. Our results also suggest bilateral retinal pathology following
unilateral ON, possibly caused by subclinical involvement of the contralateral NON eyes.
Moreover, our data may assist in clinical trial planning in studies targeting tissue damage in
acute ON.
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Optic neuritis (ON) is an acute inﬂammation of the optic nerve
and a frequent clinical manifestation of MS.1–3 Within the
retina, ON-associated neuroaxonal damage manifests as peri-
papillary retinal nerve ﬁber layer (pRNFL) and macular gan-
glion cell layer thinning, which can be detected in vivo using
optical coherence tomography (OCT).4–7 Studies have found
that pRNFL and the combined macular ganglion cell and inner
plexiform layer (GCIP) thickness strongly correlated with
functional visual outcomes in ON.8,9 A multicenter study re-
cently found that pRNFL thickness below a certain threshold
was predictive of a more disabling disease course.10 In addition
to the inner retina, changes to the outer retina (e.g., inner
nuclear layer [INL]) have been observed after ON.11–13
Of interest, previous studies have found that the clinically
unaﬀected contralateral eye may display some degree of
dysfunction following unilateral ON.14–16 Structural data to
date are only available for the outer retina over 6 months after
ON17 or for the inner retina over 12 months.18 Although
a number of cross-sectional OCT studies in ON have been
published,8,19 longitudinal studies are still scarce.12,17,18
The primary goal of this study was to describe the temporal
dynamics and magnitude of retinal structural and functional
visual damage in patients with a ﬁrst-ever ON in the aﬀected
and unaﬀected eyes. Further objectives included investigating
the association between early macular damage and visual
outcomes and exploratory analysis of sex-speciﬁc diﬀerences
during ON.
Methods
Study design
Forty-one patients with a ﬁrst-ever acute ON were identiﬁed
retrospectively by chart review, and their clinical and OCT
data were analyzed longitudinally over a period of 12 months
following the episode. Patient data were acquired at baseline
(deﬁned as symptom onset ±28 days maximum after onset of
ON) and, relative to baseline, at 1 (24–38 days), 3 (79–107
days), 6 (158–214 days), and 12 (310–434 days) months
thereafter between 2014 and 2017.
Standard protocol approvals, registrations,
and patient consents
The study was approved by the Ethics Committee of the
Canton of Zurich, Switzerland (reference KEK-ZH-Nr.2013-
0001), and all patients signed a general informed consent form.
Patients eligibility
Patients with a ﬁrst-ever episode ofON, including idiopathicON
and ON in the context of MS (diagnosed according to the 2010
revised McDonald criteria20), were included in the study. ON
was diagnosed by experienced clinicians from the Departments
of Neurology and Ophthalmology at the University Hospital
Zurich, Switzerland. Patients were included if OCT and visual
acuity assessments were performed at baseline and at least one
more of the predeﬁned time points. Exclusion criteria included
previous clinical history of ON in either eye, retinal pathology
(visible on ophthalmologic or OCT examination) or any other
ocular or systemic disease, which could aﬀect vision or retinal
structure (e.g., diabetesmellitus and uncontrolled hypertension),
refractive error ≥6.0 diopters, and history of eye surgery.
Visual acuity
High-contrast visual acuity (HCVA) and low-contrast visual
acuity (LCVA)were recorded at each visit with habitual refractive
correction. HCVA was tested using Early Treatment Diabetic
Retinopathy Study charts (100% contrast), and LCVAwas tested
with Sloan letter charts (2.5% contrast). For both, the number of
correctly identiﬁed letters was recorded and speciﬁed with the
logarithm of the minimum angle of resolution (logMAR) scale.21
Optical coherence tomography
OCTwas performed using a single Heidelberg Spectralis OCT
device (Software version 1.9.10.0; Heidelberg Engineering,
Heidelberg, Germany) by 3 experienced OCT operators. The
device is equipped with a TruTrack eye tracking program.
OCTs were performed without pupillary dilation in a darkened
room. Scans were acquired at baseline and at 1, 3, 6, and 12
months after ON. The macular volume protocol was per-
formed in high-resolution mode and involved 19 consecutive
vertical B scans (25 automatic real-time tracking, 1,536 A-scans
per B scan, 240 μmbetween B scans) crossing the macula using
an integrated macular volume protocol (“PPoleV”). The
pRNFL thickness protocol involved a high-resolution peri-
papillary ring scan (12° diameter, 30 automatic real-time
tracking) centered over the optic nerve head (ONH). For
postprocessing, retinal layer segmentation was performed au-
tomatically using the built-in Heidelberg retina angiograph/
Spectralis Viewer Module (v.6.3.4.0). The mean thickness of
the macular ganglion cell layer, inner plexiform layer, and INL
was calculated by centering the 1.00-mm, 2.22-mm, 3.45-mm
Early Treatment Diabetic Retinopathy Study grid on the fovea
and averaging the thickness of all quadrants. GCIP thickness
was the summation of the ganglion cell layer and inner plexi-
form layer. The software calculated the mean pRNFL
Glossary
DMT = disease-modifying therapy;GCIP = ganglion cell and inner plexiform layer;HCVA = high-contrast visual acuity; INL =
inner nuclear layer; LCVA = low-contrast visual acuity; logMAR = logarithm of the minimum angle of resolution; MME =
microcystic macular edema; NMOSD = neuromyelitis optica spectrum disorder; NON = nonoptic neuritis; OCT = optical
coherence tomography;ON = optic neuritis;ONH = optic nerve head; pRNFL = peripapillary retinal nerve ﬁber layer; RGC =
retinal ganglion cell; VEP = visual evoked potential.
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thickness, 360° around the ONH. All ONH scans fulﬁlled the
OSCAR-IB quality consensus criteria.22 All scans were
reviewed by a single author (C.A.W.) and, when necessary,
segmentation boundaries manually corrected. OCT data have
been reported in line with the Advised Protocol forOCT Study
Terminology and Elements recommendations (APOSTEL).23
Statistics
Statistical analyses were performed using R version 3.3.1 (R
Core Team, 2016; r-project.org). To assess whether time
between symptom onset and baseline examination may in-
ﬂuence the OCT analysis, an unpaired, 2-sample t test was
used to compare the mean baseline GCIP thickness of the ON
eyes between early (≤7 days) and late (>7 days) presenting
patients. All retinal layers derived from OCT measurements
were analyzed independently of each other. For each layer,
a linear mixed-eﬀects model was used to assess the diﬀerences
between ipsilateral ON eyes and contralateral non-ON
(NON) eyes over time. The response variable of the model
was the DGCIP, DpRNFL, or DINL (the diﬀerence between
the retinal layer thickness of an ON eye at each time point and
the retinal layer thickness of the corresponding NON eye at
baseline). All comparisons were made to the baseline of the
NON eyes assuming that the baseline of the NON eyes is
nonpathologic and therefore suitable as an intraindividual
control. This approach is further supported by previous
studies suggesting that analysis of intereye thickness diﬀer-
ences is more accurate in detecting retinal ganglion cell
(RGC) damage than absolute thicknesses24 and that within-
patients comparisons are more sensitive than comparisons to
a healthy control group.25,26 All models included time points,
age, sex, disease duration, steroid treatment (yes/no), and
disease-modifying therapy (DMT) (yes/no) as ﬁxed eﬀects
and a random eﬀect accounted for intraindividual compar-
isons; furthermore, the model is known to eﬃciently handle
missing values.27 The residuals of the model were tested for
normality with the Shapiro-Wilk test and by inspection of the
residuals and Q-Q plots. The relationship between GCIP
thickness and LCVA in ON eyes was assessed by Spearman
rank correlations. All p values were Bonferroni corrected for
multiple comparisons. p Values ≤0.05 were considered sta-
tistically signiﬁcant.
Data availability
All data from this study will be available (in anonymized form)
on reasonable request from any qualiﬁed investigator.
Results
Patient demographics and
clinical characteristics
Patient demographics and clinical characteristics obtained at
baseline clinical evaluation are detailed in table 1. In total, 41
patients (28 women and 13 men; mean age: 32.4 years) were
included in the study. Thirty patients (73.2%) had anON in the
context of MS, whereas 11 cases (26.8%) were diagnosed with
idiopathic ON. In cases with bilateral ON (n = 2), the more
severely aﬀected eye at baseline was classiﬁed as the ON eye.
From the less severely aﬀected eye, only baseline results were
analyzed and used to calculate intereye diﬀerences over time,
whereas the follow-up data were excluded. The mean time from
clinical onset of ON to baseline examination was 10 days. The
average GCIP thickness in ON eyes was not signiﬁcantly dif-
ferent (p = 0.13) between patients presenting early or late for
baseline examination. One patient had a clinical ON event
during follow-up, aﬀecting the contralateral eye at month 12;
the data for this eye at month 12 were excluded from analysis.
Structural retinal damage following ON
GCIP thickness in NON eyes remained stable, whereas GCIP
thickness in ON eyes decreased over time. The mean
DGCIP diﬀered signiﬁcantly in ON eyes at all time points
Table 1 Patient demographics and clinical characteristics
at baseline examination
Total Female Male
No. of patients 41 28 13
Mean age (SD) [y] 32.4 (9.4) 32.0 (10.8) 33.3 (5.4)
Mean disease duration (SD) [d]
Median [d] 184 (730) 207 (873) 134 (234)
Minimum [d] 2 2 2
Maximum [d] 4,611 4,611 804
Cause of ON
Idiopathic ON 11 8 3
CIS 7 6 1
RRMS 22 14 8
PPMS 1 0 1
ON presentation
Unilateral 39 27 12
Bilateral 2 1 1
Mean time from clinical onset
of ON to baseline scan (SD) [d]
10 (7) 11 (8) 8 (4)
Patients treated with
corticosteroids
37 25 12
Patients treated with DMT 17 11 6
Ethnicity
European 38 27 11
South Asian 1 0 1
West African 1 0 1
North American 1 1 0
Abbreviations: CIS = clinically isolated syndrome; DMT = disease-modifying
therapy; ON = optic neuritis; PPMS = primary progressive MS; RRMS = re-
lapsing-remitting MS.
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(p < 0.0001) post-ON (ﬁgure 1, table 2). ON eyes had a mean
GCIP reduction over the 12-month follow-up period of
14.1 μm (SD: 3.2 μm), with 74.5% of the change occurring
within the ﬁrst month and 100% within 3 months following
ON (ﬁgure 1, table 2). Except for time points, none of the
covariates (age, sex, disease duration, steroid treatment, and
DMT) appeared to have a signiﬁcant eﬀect on the response
variables (DGCIP, DpRNFL, or DINL), but were neverthe-
less included in the statistical model, as preplanned. In com-
parison, the mean longitudinal GCIP thickness in NON eyes
showed an absolute reduction of 1.1 μm (SD: 2.2 μm) over
the same period (table 3).
Although we observed numerical diﬀerences between men
and women in terms of GCIP reduction after 12 months
(men: −19.8 μm, SD: 4.9 μm vs women: −10.3 μm, SD:
4.1 μm), these diﬀerences did not reach statistical signiﬁcance
(tables e-1 and e-2, links.lww.com/NXI/A187).
Mean baseline pRNFL thickness in ON eyes was 116.2 μm
(SD: 29.3 μm) and had an average thickness diﬀerence of
+18.2 μm (SD: 4.8 μm) compared with contralateral NON
eyes (table 2, ﬁgure 1). The mean DpRNFL was signiﬁcantly
diﬀerent at months 1 (p < 0.05), 3 (p < 0.0001), 6 (p <
0.0001), and 12 (p < 0.0001) post-ON. Although most of the
total pRNFL reduction (87.8%) occurred within the ﬁrst 3
months post-ON, thickness continued to slowly decline up
until month 12 (table 1). In NON eyes, mean pRNFL
thickness values between 96.0 μm and 99.0 μm were reported
over the 12-month period (table 3). At baseline, women had
a mean pRNFL thickness of 113.9 μm (SD: 31.3 μm) in ON
eyes and a diﬀerence of +15.79 μm (SD: 6.1 μm) compared
with their respective NON eyes, whereas the ON eyes in men
had a mean pRNFL thickness of 121.0 μm (SD: 24.9 μm) and
a diﬀerence of +23.4 μm (SD: 7.4 μm) compared with the
respective NON eyes. By month 6, women and men had
almost identical mean pRNFL thicknesses. Subsequent to
month 6, pRNFL thickness stabilized until month 12 in
women, whereas men experienced a further decline (tables
e-1 and e-2, links.lww.com/NXI/A187).
The baseline mean INL thickness was similar in NON and
ON eyes (table 2, ﬁgure 1). However, a signiﬁcant intereye
diﬀerence between month 1 macular INL thickness in ON
eyes and baseline contralateral INL thickness (p < 0.05) was
found (ﬁgure 1).
The INL thickness in ON eyes showed more pronounced
changes over time in men than in women. At month 1 fol-
lowing ON, mean INL thickness was similar in men and
women. In female ON eyes, mean INL thickness remained
nearly unchanged up to month 12, whereas in male ON eyes,
mean INL thickness increased by 3.0 μm (SD: 1.6 μm) at
month 12 (tables e-1 and e-2, links.lww.com/NXI/A187).
In NON eyes, almost no change in mean INL thickness was
observed at months 1, 3, and 6, but there was a signiﬁcant
increase at month 12 (+1.4 μm, SD: 1.1 μm, p < 0.05) com-
pared with baseline (table 3). Although small in magnitude,
this increase nevertheless represents a change of +3.9% by
month 12 compared with the baseline examination.
Visual functional changes following ON
Visual acuity of ON eyes was lowest at the acute phase of ON
and was worse compared with that of NON eyes (ﬁgure 2,
table e-3, links.lww.com/NXI/A187). Subsequently, visual
acuity recovered partially; although HCVA improved rapidly
in ON eyes and was comparable to measurements in the
NON eyes already at month 3, LCVA never reached the level
of NON eyes during the entire observation period (ﬁgure 2).
Namely, ON eyes displayed a mean LCVA intereye diﬀerence
of 0.23 logMAR, corresponding to 11–12 letters at month 12.
Association between macular damage and
visual outcomes
Thinner GCIP thickness at month 1 was correlated with lower
LCVA at month 3 (rho = −0.63, p = 0.01) in ON eyes. No
statistically signiﬁcant relationship was found between GCIP
thickness and LCVA at month 6 or 12. Furthermore, no
associations were observed betweenGCIP thickness at month
1 and HCVA at any time point.
Discussion
We found that an episode of acute ON can result in extensive
neuroaxonal retinal damage of the ipsilateral eye, conﬁrming
previous longitudinal reports.17,18 Signiﬁcant GCIP thinning
was already detectable at 1 month after ON and also at all
subsequent time points.
The status of the retina distal to GCIP beyond 6 months
post-ON has previously not been documented. We mea-
sured a small but signiﬁcant increase in INL thickness in the
clinically (seemingly) unaﬀected NON eyes at month 12,
suggestive of bilateral retinal pathology in clinically unilat-
eral ON.
Similarly, a signiﬁcant intereye diﬀerence between month 1
INL thickness in ON eyes and baseline contralateral INL
thickness was observed. Although the detected changes are
numerically small, the INL thickness increase in the ON eyes
recorded was similar in magnitude to previous ﬁndings, in-
cluding a large meta-analysis.12 All these previously reported
changes to INL thickness, including the current ﬁndings, are
below the axial resolution of the OCT device used in this
study (;5 μm); however, several studies have recorded that
the detection limit for retinal layer thickness changes is ap-
proximately 1 μm.28,29 Thus, it is likely that the observed INL
thickening is meaningful. Nevertheless, it may be prudent to
be cautious when interpreting such ﬁndings at the individual
patient level. Recently, it has been suggested that the INL
shows promise as a possible marker of MS inﬂammatory
disease activity and response to treatment, with INL
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Figure 1 Longitudinal retinal thickness in ON
(A) Reduction in mean macular GCIP thickness in ON
eyes at baseline and in the subsequent 12 months
compared with baseline mean GCIP thickness in NON
eyes (****p < 0.0001). (B) Mean pRNFL thickness in NON
and ON eyes at baseline and in the subsequent 12
months (*p < 0.05, ****p < 0.0001). (C) Intereye differ-
ence between macular INL thickness in ON eyes and
baseline contralateral INL thickness (*p < 0.05). Intraeye
difference in macular INL thickness in NON eyes over
time (**p < 0.05). Error bars represent SDs. GCIP =
ganglion cell and inner plexiform layer; INL = inner nu-
clear layer; NON = nonoptic neuritis; ON = optic neuritis;
pRNFL = peripapillary retinal nerve fiber layer.
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thickening being associated with more active or breakthrough
disease.7,29–31 Therefore, INL thickening in ON eyes may be
due tomechanisms related to inﬂammation within or aﬀecting
the INL.7,29,30 Increased INL thickness has also been associ-
ated with the presence of microcystic macular edema (MME),
particularly in patients with a history of MS-related ON or
neuromyelitis optica spectrum disorders (NMOSDs).31,32 In
our cohort, signs of MME were only observed in 1 patient, in
whom only pRNFL data were analyzed. Moreover, none of
the 11 idiopathic ON cases could be conﬁrmed as NMOSD33
(8 were seronegative for aquaporin-4 antibodies [AQP4-IgG],
whereas the other 3 were untested). Neither MME nor
NMOSD appears to explain the mean INL increase we
detected.
Table 2 Retinal thickness in NON eyes at baseline and in ON eyes over a 12-month period
NON ON
M0 M0 M1 M3 M6 M12
Macular GCIP
Mean (SD) [μm] 85.0 (7.4) 84.0 (8.0) 74.5 (8.0) 70.7 (11.2) 73.6 (9.6) 70.8 (11.4)
Absolute change (SD) [μm] NA −0.9 (1.8) −10.5 (2.1) −14.3 (2.5) −11.4 (2.4) −14.1 (3.2)
No. of eyes 40 36 21 25 22 15
pRNFL
Mean (SD) [μm] 98.0 (8.9) 116.2 (29.3) 103.2 (14.7) 88.4 (14.3) 89.7 (10.2) 87.1 (14.9)
Absolute change (SD) [μm] NA 18.2 (4.8) 5.3 (3.4) −9.6 (3.2) −8.2 (2.6) −10.9 (4.1)
No. of eyes 41 41 22 25 22 15
Macular INL
Mean (SD) [μm] 35.8 (2.9) 35.5 (2.6) 36.7 (3.1) 36.5 (3.1) 36.4 (2.6) 37.7 (3.8)
Absolute change (SD) [μm] NA −0.4 (0.6) 0.8 (0.8) 0.7 (0.8) 0.6 (0.7) 1.9 (1.1)
No. of eyes 40 36 21 25 22 15
Abbreviations: GCIP = ganglion cell and inner plexiform layer; INL = inner nuclear layer; M0 = month 0; M1 = month 1; M3 = month 3; M6 = month 6; M12 =
month 12; NA = not applicable; NON = nonoptic neuritis eye; ON = optic neuritis, pRNFL = peripapillary retinal nerve fiber layer.
Table 3 Retinal thickness in NON eyes over a 12-month period
M0 M1 M3 M6 M12
Macular GCIP
Mean (SD) [μm] 85.0 (7.4) 87.1 (7.0) 83.6 (9.0) 84.0 (8.3) 83.9 (7.0)
Absolute change (SD) [μm] NA 2.1 (1.9) −1.4 (2.1) −0.9 (2.1) −1.1 (2.2)
No. of scans 40 21 24 21 15
pRNFL
Mean (SD) [μm] 98.0 (8.9) 99.0 (7.6) 96.0 (9.5) 98.0 (9.9) 98.2 (9.4)
Absolute change (SD) [μm] NA 1.1 (2.1) −2.0 (2.4) 0.0 (2.5) 0.2 (2.8)
No. of scans 41 21 24 21 15
Macular INL
Mean (SD) [μm] 35.8 (2.9) 35.1 (2.4) 36.0 (2.6) 35.9 (2.4) 37.2 (3.8)
Absolute change (SD) [μm] NA −0.7 (0.7) −0.2 (0.7) 0.1 (0.7) 1.4 (1.1)
No. of scans 40 21 24 21 15
Abbreviations: GCIP = ganglion cell and inner plexiform layer; INL = inner nuclear layer; M0 = month 0; M1 = month 1; M3 = month 3; M6 = month 6; M12 =
month 12; NA = not applicable; NON = nonoptic neuritis eye; pRNFL = peripapillary retinal nerve fiber layer.
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The change in INL thickness in the NON eyes may indicate
subclinical involvement of the fellow eyes in our patients with
ON. Although this structural ﬁnding is novel in the literature,
we may draw parallels with 2 results from functional studies
and data from a clinical trial in ON. Schnurman et al.15
showed abnormalities of the ONH component of the multi-
focal electroretinogram in ON eyes but also, to a lesser extent,
in the NON eyes of the same patients. In a substudy of a re-
cent clinical trial assessing the monoclonal anti-LINGO-1
antibody opicinumab in acute ON, fellow eyes of placebo-
treated, but not opicinumab-treated, patients showed pro-
gressive multifocal visual evoked potential (VEP) amplitude
loss over 8 months.34 Similarly, Raz et al.16 found changes to
the latency of late peaks of the VEP of NON eyes, which were
not attributable to demyelination; the authors attributed these
changes to an adaptive mechanism to maximize preservation
of stereopsis in their patients with unilateral ON. We are
unable to reach ﬁrm conclusions as to the etiology of our INL
thickness changes, but we suggest subclinical inﬂammation of
the fellow eye as a potential candidate. Alternatively, given the
proposed role of the INL as a marker for global inﬂammatory
disease activity in MS, the increased INL thickness in NON
eyes at month 12 may be indicative of ongoing or future
disease activity independent of ON. However, the fact that
Balk et al.35 did not observe a signiﬁcant annualized change in
INL volume in MS eyes without a recent history of ON may
argue against this hypothesis.
By month 12, the magnitude of macular GCIP thinning was
−16.6% in ON eyes relative to the baseline of contralateral
NON eyes. An important ﬁnding of our study is the extremely
rapid evolution of macular GCIP atrophy in aﬀected eyes,
with nearly 75% of the entire reduction observed over 12
months occurring within the ﬁrst month of presentation and
100% occurring by month 3. Gabilondo et al.17 described
comparable temporal dynamics of GCIP atrophy subsequent
to ON, reporting 57.2% of the total reduction in thickness
occurring within the ﬁrst 2 months and 73.4% within the ﬁrst
3 months. Our results have important implications for future
interventions and clinical trial design: as the magnitude of
change is most pronounced early in the course of ON, very
early, if not prophylactic intervention, may be the best strategy
to prevent tissue damage in acute ON. Moreover, sample size
calculations for future clinical trials may be based on the data
presented here. Notably, NON eyes had some level of RGC
degeneration above thresholds of physiologic aging,36 con-
sistent with a recent report on longitudinal retinal changes in
NON eyes among patients with MS and again suggesting
subclinical involvement of the contralateral eye in ON.17
pRNFL thickness of ON eyes was increased at baseline ex-
amination, most likely indicative of inﬂammatory edema. At
month 1, peripapillary thickening was still evident but had
reduced substantially. Subsequently, pRNFL reduced in
thickness, reaching most of its total reduction (87.8%) by
month 3 and showing a moderately sustained decline until
month 12, in line with previous studies.18,37
To ensure that our data regarding the temporal course of
GCIP, pRNFL, and INL thickness changes are not artifactual
(due to assessing diﬀerent patients at diﬀerent time points),
we performed a subanalysis of patients who had both baseline
and month 12 examinations. The results of this subanalysis
conﬁrmed GCIP and pRNFL thinning, as well as INL thick-
ening, 1 year after ON (data not shown).
Treatment with corticosteroids (mean time between onset of
ON and administration: 10 days) was included as a di-
chotomous variable in the statistical model and was found to
have no signiﬁcant inﬂuence on the OCT measures assessed.
Figure 2 Longitudinal visual acuity in ON
Best-corrected mean HCVA (A) and LCVA (B) measures in ON eyes and NON eyes over a 12-month period. Error bars represent SDs. HCVA = high-contrast
visual acuity; LCVA = low-contrast visual acuity; logMAR = logarithm of the minimum angle of resolution; NON = nonoptic neuritis; ON = optic neuritis.
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In NMOSD, the eﬀect of steroids on visual outcomes appears
to depend critically on the timing of application, with an
optimal eﬀect being achieved with administration ≤4 days
after onset.38 Yet, in MS-associated ON, both timing and
overall impact of steroid treatment have not been shown
conclusively. Future studies may consider including temporal
information on steroid treatment as a continuous variable in
the statistical models.
A profound reduction in HCVA and LCVA was observed in
ON eyes at baseline. AlthoughHCVA recovered rapidly in the
majority of patients, with the mean reaching the level of the
unaﬀected eye at month 6, LCVA remained impaired for the
entire study period, with a clinically relevant9 intereye dif-
ference of 11–12 letters.
We also addressed a putative link between early changes to
macular architecture after ON and subsequent visual functional
loss. LCVA at month 3 tended to be worse in ON eyes with
GCIP thinning at month 1. The lack of a signiﬁcant association
between early GCIP thickness and LCVA at months 6 or 12
may be due to diminished statistical power with smaller sample
sizes at these time points. No correlation was found between
early GCIP thickness and HCVA at any time point during
follow-up, which is unsurprising, given the functional im-
provement in HCVA up to the level of the contralateral eye at
month 6. Together, these results illustrate the importance of
LCVA monitoring to properly identify functional visual re-
covery in MS-associated ON.
An exploratory objective of the study was to analyze sex-
speciﬁc diﬀerences in the outcome of acute ON episodes.
Female preponderance is well known in MS. However, pre-
vious studies have reported that once the disease manifests,
men are more severely aﬀected than women, characterized by
a more rapid disease progression and worsening of clinical
outcomes.39 To date, few studies have looked into potential
inﬂuences of sex eﬀects on visual outcomes in ON.18,40 Those
studies that have analyzed the eﬀects of sex on recovery after
ON have suggested poorer outcomes in men.18,40 Although
our raw data were consistent with these previous ﬁndings
(men demonstrated greater structural changes in GCIP,
pRNFL, and INL thickness compared with women), our
analyses did not reveal statistically signiﬁcant eﬀects of sex.
This may be due to the low number of males included in our
study (n = 13). As previous work did not state explicitly
whether results were corrected for multiple testing,18,40 it
remains possible that our negative ﬁndings regarding sex also
reﬂect diﬀerences in statistical analysis methods.
Our study has a number of limitations. As a consequence of its
retrospective nature, data were not available for all patients at
each follow-up time point, resulting in a smaller sample size at
follow-ups compared with baseline and also in a slightly dif-
ferent cohort at each time point. In addition, the study lacked
a dedicated healthy control group. Although all comparisons
were made to the baseline of the NON eyes based on the
assumption that the baseline of the NON eyes is non-
pathologic, it cannot be completely ruled out that NON eyes
previously experienced retinal pathology following subclinical
ON. The latter also holds true for the ON eyes.
The characterization of temporal dynamics underlying neu-
roaxonal damage in ON and factors associated with a poor
functional outcome is important for optimizing timing, pa-
tient selection, and mechanisms to target in future inter-
ventions. Thus, future prospective studies in ON including
the contralateral eyes are needed to conﬁrm the ﬁndings
reported here in larger cohorts. Such studies may also add
clinical relapse rate or radiologic disease activity as outcomes
to better assess the clinical signiﬁcance of the OCT ﬁndings
reported and to further improve our understanding of the
basic mechanisms underlying tissue damage in ON. Such
results may pave the way for targeted interventions with the
aim of reducing functional visual sequelae.
Overall, our results indicate that macular structural damage
develops rapidly in patients with acute ON in aﬀected eyes
and correlates with functional visual outcomes. LCVA re-
covery is incomplete following an episode of acute ON. We
also provide preliminary evidence for structural pathology
involving the contralateral, clinically unaﬀected eyes, which
may be explained by subclinical involvement of the fellow eye
in ON. Our results further strengthen the importance of early
intervention when planning for clinical trials targeting tissue
protection in acute ON.
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